Johnson Memorial Health Services
Johnson Memorial Health Services was paid $194K by Medicaid between Jan 2018 and Dec 2024, across 18 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 25% of everything it billed.
DAWSON, MN 56232
Next to other Critical Access Hospital providers in Minnesota
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 467 | $3K | |
| 2019 | 615 | $8K | |
| 2020 | 942 | $45K | |
| 2021 | 929 | $46K | |
| 2022 | 1,266 | $44K | |
| 2023 | 1,395 | $34K | |
| 2024incomplete | 466 | $13K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 25% | 554 | 325 | $49K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 21% | 1,840 | 806 | $41K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 12% | 897 | 255 | $23K |
| 36415 | Collection of venous blood by venipuncture | 12% | 1,648 | 1,357 | $23K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 9.1% | 66 | 62 | $18K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 8.4% | 53 | 49 | $16K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 6.4% | 540 | 216 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.1% | 83 | 78 | $6K |
| J3490 | Unclassified drugs | <1% | 54 | 25 | $2K |
| 97803 | <1% | 54 | 54 | $994.10 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32 | 25 | $854.36 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 75 | 72 | $708.74 |
6 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24 | $691.77 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12 | $446.74 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $377.45 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 46 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 59 | $0.00 |
| 90686 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.